{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:43:31Z","timestamp":1772750611775,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2020,12,23]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Recent studies have observed overexpression of histone deacetylase 7\n(HDAC7) and overactivity of extracellular signal-regulated kinases 1\/2 (ERK1\/2) in many tumors;\ntherefore, pharmacological interventions to inhibit overexpression of HDAC7 and overactivity of\nERK1\/2 in cancerous cells holds great promise in cancer treatment. The promising anticancer\nproperties of artemisinin and artemisinin-derivatives (ARTs) have been validated by various experimental\nreports, including advanced pre-clinical trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Our aim in this in silico study is to identify additional inhibitors of HDAC7, ERK1 and\nERK2 as potential anticancer drug agents and provide insight into the molecular level of interactions\nof such ligands relative to known standards.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>To achieve this aim, the binding affinities of ulixertinib (the standard ERK inhibitor),\napicidin (the standard HDAC7 inhibitor) as well as 49 ARTs for HDAC7, ERK1 and ERK2 were\nevaluated using AutodockVina. The molecular binding interactions of compounds with remarkable\nbinding affinity for all the 3 target proteins, relative to their respective standards, were viewed with\nDiscovery Studio Visualizer, BIOVIA, 2016.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Out of the 49 ARTs, our study identified 2 compounds, artemisinin dimer and artemisinin\ndimer hemisuccinate, as having higher binding affinities for all the target proteins compared to\ntheir respective standard inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> These findings suggest that artemisinin dimer and artemisinin dimer hemisuccinate\ncould be promising anticancer drug agents, with better therapeutic efficacy than ulixertinib and\napicidin for the treatment of cancer via inhibition of HDAC7, ERK1 and ERK2.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163816666190705164756","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:40:55Z","timestamp":1562672455000},"page":"725-734","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["<i>In Silico<\/i> Screening Reveals Histone Deacetylase 7 and ERK1\/2 as Potential Targets for Artemisinin Dimer and Artemisinin Dimer Hemisuccinate"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-5922","authenticated-orcid":true,"given":"Ahmed A.","family":"Ishola","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, Ilorin, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-3798","authenticated-orcid":true,"given":"Kayode E.","family":"Adewole","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Basic Medical Sciences, University of Medical Sciences Ondo, Ondo State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/173280","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/173280\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/173280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T14:44:18Z","timestamp":1609166658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/173280\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,12,23]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163816666190705164756","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}